ABSTRACT
OBJECTIVES: 1.) To compare frequency of HIPEC use in ovarian cancer treatment before and after publication of the phase III study by van Driel et al. in January 2018. 2.) To compare associated rates of hospital-based outcomes, including length of stay, intensive care unit (ICU) admission, complications, and costs in ovarian cancer surgery with or without HIPEC. METHODS: We queried Vizient's administrative claims database of 550 US hospitals for ovarian cancer surgeries from January 2016-January 2020 using ICD-10 diagnosis and procedure codes. Sodium thiosulfate administration was used to identify HIPEC cases according to the published protocol. Student t-tests and relative risk (RR) were used to compare continuous variables and contingency tables, respectively. RESULTS: 152 ovarian cancer patients had HIPEC at 39 hospitals, and 20,014 ovarian cancer patients had surgery without HIPEC at 256 hospitals. Following the trial publication, 97% of HIPEC cases occurred. During the index admission, HIPEC patients had longer median length of stay (8.4 vs. 5.7 days, p < 0.001) and higher percentage of ICU admissions (63.1% vs. 11.0%, p < 0.001) and complication rates (RR = 1.87, p = 0.002). Index admission direct costs ($21,825 vs. $12,038, p < 0.001) and direct cost index (observed/expected costs) (1.87 vs. 1.11, p < 0.001) were also greater in the HIPEC patients. No inpatient deaths or 30-day readmissions were identified after HIPEC. CONCLUSIONS: Use of HIPEC for ovarian cancer increased in the US after publication of a phase III clinical trial in a high-impact journal, though the absolute number of cases remains modest. Incorporation of HIPEC was associated with increased cost, hospital length of stay, ICU admission, and hospital-acquired complication rates. Further studies are needed in order to evaluate long-term outcomes, including morbidity and survival.
Subject(s)
Carcinoma, Ovarian Epithelial/therapy , Cytoreduction Surgical Procedures/adverse effects , Hyperthermic Intraperitoneal Chemotherapy/trends , Ovarian Neoplasms/therapy , Postoperative Complications/epidemiology , Aged , Aged, 80 and over , Carcinoma, Ovarian Epithelial/economics , Carcinoma, Ovarian Epithelial/mortality , Clinical Trials, Phase III as Topic , Female , Hospital Costs/statistics & numerical data , Hospital Costs/trends , Humans , Hyperthermic Intraperitoneal Chemotherapy/adverse effects , Hyperthermic Intraperitoneal Chemotherapy/economics , Hyperthermic Intraperitoneal Chemotherapy/statistics & numerical data , Intensive Care Units/economics , Intensive Care Units/statistics & numerical data , Intensive Care Units/trends , Length of Stay/economics , Length of Stay/statistics & numerical data , Male , Middle Aged , Ovarian Neoplasms/economics , Ovarian Neoplasms/mortality , Ovary/drug effects , Ovary/surgery , Patient Admission/economics , Patient Admission/statistics & numerical data , Patient Admission/trends , Postoperative Complications/economics , Postoperative Complications/etiology , Retrospective Studies , United States/epidemiologySubject(s)
Carcinoma/therapy , Colorectal Neoplasms/therapy , Cytoreduction Surgical Procedures/statistics & numerical data , Hyperthermic Intraperitoneal Chemotherapy/statistics & numerical data , Peritoneal Neoplasms/therapy , Antineoplastic Agents/administration & dosage , Carcinoma/mortality , Carcinoma/secondary , Colorectal Neoplasms/mortality , Colorectal Neoplasms/pathology , Cytoreduction Surgical Procedures/trends , Disease-Free Survival , Evidence-Based Medicine/methods , Humans , Hyperthermic Intraperitoneal Chemotherapy/trends , Peritoneal Neoplasms/mortality , Peritoneal Neoplasms/secondary , Progression-Free Survival , Randomized Controlled Trials as Topic/statistics & numerical dataABSTRACT
BACKGROUND: Several hospitals have implemented a multidisciplinary Acute Pain Service (APS) to execute surgery-specific opioid sparing analgesic pathways. Implementation of an anesthesia attending-only APS has been associated with decreased postoperative opioid consumption, time to ambulation, and time to solid food intake for patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. In this study, we evaluated the impact of introducing an APS trainee on postoperative opioid consumption in patients undergoing hyperthermic intraperitoneal chemotherapy during POD 0-3. METHODS: We performed a retrospective propensity-matched cohort study where we compared opioid consumption and hospital length of stay among two historical cohorts: attending-only APS service versus service involving a regional anesthesia fellow. RESULTS: In the matched cohorts, the median postoperative day (POD) 0-3 opioid use [25%, 75% quartile] for the single attending and trainee involvement cohort were 38.5 mg morphine equivalents (MEQ) [14.1 mg, 106.3 mg] and 50.4 mg MEQ [28.4 mg, 91.2 mg], respectively. The median difference was -9.8 mg MEQ (95% CI -30.7-16.5 mg; P = 0.43). There was no difference in hospital length of stay between both cohorts (P = 0.67). CONCLUSIONS: We found that the addition of a regional anesthesia fellow to the APS team was not associated with statistically significant differences in total opioid consumption or hospital length of stay in this surgical population. The addition of trainees to the infrastructure, with vigilant supervision, is not associated with change in outcomes.